Clinical trials: Rosuvastatin
Hypertension, Hyperlipidemia
Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg
To compare the safety and pharmacokinetics between ROVATITAN tab. 160/20 mg (ROVATITAN tab 160/20mg-1, ROVATITAN tab. 160/20mg-2) and coadministration of Diovan® (Valsartan) 160 mg and Crestor® (Rosuvastatin) 20 mg in healthy…
- Trial name
- NCT01918358
- Testing
- Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R), Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1), Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Essential Hypertension, Dyslipidemia
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of combination of Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with essential hypertension and dyslipidemia.
- Trial name
- NCT02166814
- Testing
- Fimasartan and Rosuvastatin, Fimasartan, Rosuvastatin
- Where
- 26 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Metabolic Syndrome, Dyslipidemia
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
The purpose of this study is to investigate the dose-related effect of treatment with rosuvastatin on production and fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), and on the plasma…
- Trial name
- NCT00240305
- Testing
- Rosuvastatin
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics
Each subject will be given a single oral dose of rosuvastatin on Day 1 in Period 1. In Period 2, after a washout period of at least 5 days, each subject will receive oral doses of tafamidis twice daily (BID) on days 1 and 2…
- Trial name
- NCT04253353
- Testing
- tafamidis, rosuvastatin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia, Hyperlipidemias
Ezetimibe-Rosuvastatin Evaluation Study
Evaluation of the efficacy of the stable ezetimibe-rosuvastatin combination in patients with primary hypercholesterolemia in achieving the target plasma LCL-C level.
- Conditions
- Hypercholesterolemia, Hyperlipidemias, Combinations of Drugs; Dependence
- Trial name
- ZEUS (NCT03947866)
- Where
- Greece
- Volunteers
- 600 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Hypercholesterolemia, Coronary Heart Disease
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg
The purpose of this study is to compare 6 weeks of treatment with rosuvastatin alone compared with 6 weeks of treatment of rosuvastatin combined with ezetimibe in achieving low density lipoprotein level goals.
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
- Trial name
- EXPLORER (NCT00653445)
- Testing
- Rosuvastatin, Ezetimibe
- Sponsor
- AstraZeneca
Dyslipidemias
Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects
The purpose of this study is to evaluate the drug interaction between CKD-519 and rosuvastatin in healthy male subjects.
- Trial name
- NCT03175835
- Testing
- Rosuvastatin 20 mg, CKD-519 200 mg, Rosuvastatin 20 mg & CKD-519 200 mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Male
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
This is a phase I study to evaluate drug-drug interactions (DDIs) of D-1553 as a perpetrator combined with midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), rosuvastatin (OATP1B1/OATP1B3 substrate), furosemide…
- Trial name
- NCT06105255
- Testing
- D-1553
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Myocardial Ischaemia, Coronary Artery Disease
Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease
The purpose of this study is to determine whether treatment with 40mg of Rosuvastatin for 8 weeks will reduce the number of episodes of myocardial ischaemia suffered in subjects with coronary artery disease.
- Trial name
- NCT00657527
- Testing
- Rosuvastatin, Cholesterol lowering diet
- Volunteers
- 280 people
- Sponsor
- AstraZeneca
Hypertension, Hyperlipidemia
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia
Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.
- Trial name
- NCT03067688
- Testing
- Temisartan+Amlodipine+Rosuvastatin (Combination drug), Temisartan+Amlodipine, Temisartan+Rosuvastatin
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Yuhan Corporation
Dyslipidemia, Hyperlipidemia
Rosuvastatin Adherence App Study in China
This is a randomized, two-arm, open label, Phase IV clinical trial to evaluate if the provision of a smart phone-based patient support tool prolongs the patient's rosuvastatin treatment duration.
- Trial name
- eHELP China (NCT02433288)
- Testing
- Smart phone based patient support tool, Control application: only for data collection
- Where
- 25 sites in China
- Volunteers
- 885 people
- Sponsor
- AstraZeneca
Metabolic Disease
Safety, Tolerability and PK of PXL770 in Healthy Male Subjects
PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03395470
- Testing
- PXL770, Rosuvastatin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Poxel SA
Atherosclerotic Cardiovascular Disease, Type 2 Diabetes Mellitus
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
This study will evaluate the efficacy and aafety of rosuvastatin/ezetimibe combination therapy vs. rosuvastatin monotherapy in atherosclerotic cardiovascular disease patients with type 2 diabetes mellitus
- Trial name
- MIRA (NCT03597412)
- Testing
- Rosuvamibe, Monorova
- Where
- South Korea
- Volunteers
- 236 people
- Sponsor
- Yuhan Corporation
Healthy Subjects
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
Effect of hetrombopag on the pharmacokinetics of rosuvastatin in healthy subjects.
- Trial name
- NCT05088343
- Testing
- Rosuvastatin, Hetrombopag
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Atherosclerosis
To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers
The potential for a drug interaction between Darapladib and Rosuvastatin is felt to be low and it would be helpful to quantify this risk in man in order to guide prescribing physicians.
- Trial name
- NCT01751074
- Testing
- Rosuvastatin 10 mg, Darapladib 160 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypercholesterolaemia
Rosuvastatin Calcium Bioequivalence Study - Fast
This is an open-label, randomized, two treatment, two sequences, two periods crossover study, using a crossover 2x2 design, where each subject will be randomly assigned to reference or test formulation, in order to evaluate if…
- Trial name
- NCT01711749
- Testing
- Crestor®, rosuvastatin calcium tablets
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer Study
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir and Digoxin or Rosuvastatin
- Trial name
- NCT06921941
- Testing
- Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR
- Where
- Canada
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Dyslipidemias
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with dyslipidemia in routine medical practice.
- Trial name
- TREZETE (NCT04862962)
- Testing
- Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
- Where
- Mexico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Type IIa and IIb Hypercholesterolaemia
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
The purpose of this study is to evaluate the efficacy and safety of Rosuvastatin 5 mg as an hypercholesterolemia treatment comparatively at 2 other statins: Pravastatin 40 mg and Atorvastatin 10 mg.
- Trial name
- CAP-Chol (NCT00631189)
- Testing
- Rosuvastatin, Pravastatin, Atorvastatin
- Where
- 170 sites in France
- Volunteers
- 668 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin
This study will assess the effect of multiple doses of AZD5462 on the PK of oral midazolam (CYP3A4 probe), rosuvastatin (OATP1B1/3, BCRP probe), and digoxin (P-gp probe) in healthy participants.
- Trial name
- NCT05395117
- Testing
- AZD5462, Midazolam, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca